for the Alzheimer's Disease Genetics Consortium and the Alzheimer's Disease Neuroimaging Initiative IMPORTANCE The strongest genetic risk factor for Alzheimer disease (AD), the apolipoprotein E(APOE) gene, has a stronger association among women compared with men. Yet limited work has evaluated the association between APOE alleles and markers of AD neuropathology in a sex-specific manner.
tangle pathology.
11 This article will focus on amyloid and tau as potential contributors to sex differences in the clinical effects of APOE.
In the case of amyloid pathology, APOE-ε4 has a strong association with amyloidosis, 8, 9 even among older adults without dementia, 12 likely through its role in amyloid clearance. 13 Research leveraging in vivo biomarkers of amyloid has indicated that the association between APOE-ε4 and amyloidosis is consistent across sexes, 8,14-16 yet other work has found evidence of age-dependent sex differences in the effects of APOE-ε4 on amyloidosis. 17, 18 In the case of tau pathology, APOE-ε4 is associated with higher levels of cerebrospinal fluid (CSF) tau 19 and more neurofibrillary tangles at autopsy, 11 although these associations are relegated to individuals with high levels of amyloid pathology. 16 The evidence of a sex difference in the association between APOE and tau pathology is also mixed, with some biomarker 15, 19 and autopsy 18 work suggesting women show a more robust association between APOE-ε4 and tau, while other work has reported no sex difference. 14, 20, 21 Collectively, the amyloid and tau findings to date provide mounting, although inconclusive, evidence of a sex difference in the association between APOE and both of the primary neuropathological hallmarks of AD. The objective of this study was to provide a comprehensive understanding of the sex-specific associations between APOE and AD neuropathology in older adulthood. The pooled data resources for this project provide the opportunity to evaluate sex differences across the spectrum of normal aging and AD including a broad range of age and cognitive status. The first set of analyses focused on 4 in vivo data sets that include CSF biomarkers of AD neuropathology. The second set focused on 6 autopsy data sets of AD leveraging direct measures of AD neuropathology. Together, these analyses provide a thorough and needed investigation into sexspecific effects of APOE on AD neuropathology.
Methods
Data were acquired from well-characterized studies of AD (Tables 1 and 2 ). The biomarker database included 4 cohort studies. The Vanderbilt Memory & Aging Project (VMAP), launched in 2012, recruited participants 60 years and older from the community who were magnetic resonance imaging eligible and free of dementia and clinical stroke. 22 The Wisconsin Registry of Alzheimer's Prevention began in 2001, recruiting participants aged 40 to 65 years. Seventy-two percent (n = 1112) have a parent with either probable AD dementia ascertained through medical history review or autopsyconfirmed AD. 23 The Biomarkers of Cognitive Decline Among
Normal Individuals study began in 1995. Enrollees were middle age at baseline and cognitively intact; 75% of participants (n = 266) had a first-degree relative with AD. The study stopped in 2005 and was reestablished in 2009, with annual assessments. 24 The Alzheimer's Disease Neuroimaging Initiative (ADNI) launched in 2003 and includes more than 1500 adults aged 55 to 90 years with normal cognition, mild cognitive impairment, or AD (http://www.adni-info.org). The autopsy database was derived from data published by Beecham et al 25 evaluating genetic markers of AD neuropathology, which includes cohort descriptions. 25 The Translational Genomics Research Institute, National Institute on Aging Late-Onset Alzheimer's Disease Family Study, and Mayo Clinic were analyzed directly from the published data. 25 The data set was updated using data from the Religious Orders Study and Rush Memory and Aging Project, the Adult Changes in Thought study, and the National Alzheimer's Coordinating Center data set. Briefly, the Religious Orders Study began in 1994 and involves older Catholic nuns, priests, and brothers recruited from across the United States. Rush Memory and Aging Project began in 1997 and involves older lay persons recruited from retirement communities, subsidized housing facilities, and social service agencies in the Chicago, Illinois, metropolitan area. Persons in both studies enrolled without dementia and agreed to annual clinical evaluations and organ donation at death. 26, 27 The Adult Changes in Thought began in 1994 and recruited a random sample of older adults without dementia from the Seattle, Washington, metropolitan area. A subset of participants in Adult Changes in Thought (25%-30%) also agreed to brain donation. 28 The National Alzheimer's Coordinating Center maintains a database of participant information collected from 34 past and present National Institute of Aging-funded Alzheimer's Disease Centers. Indeath. The collection of VMAP data and secondary analyses of all data were approved by the Vanderbilt University Medical Center institutional review board. All study participants provided written consent to the data collection and laboratory analyses proposed as part of their participation in the primary studies.
APOE Genotyping
As previously reported, 29 APOE haplotypes (ε2, ε3, and ε4)
were determined using single-nucleotide polymorphisms rs7412 and rs429358 in Adult Changes in by the same laboratory using the same procedure. Given known batch effects, we analyzed variables as continuous squareroot-transformed outcomes within each data set individually and used an analysis based on standardized coefficients to summarize results across data sets.
Quantification of Neuropathology Outcomes
Within the autopsy data sets, we used a measure of neurofibrillary tangles (Braak staging) 33 and a measure of neuritic plaques (Consortium to Establish a Registry for Alzheimer's Disease [CERAD] neuritic plaque score) 34 in each data set. Both measures were analyzed as binary outcomes and as ordinal outcomes. The binary neuritic plaque positive score was defined based on CERAD, whereby scores of none or sparse neuritic plaques were considered neuritic plaque negative, and scores of moderate or frequent neuritic plaques were considered neuritic plaque positive. The binary neurofibrillary tangles positive score was defined based on Braak staging, whereby stages none, I, or II were considered neurofibrillary tangle negative and stages III, IV, V, or VI were considered neurofibrillary tangle positive.
Statistical Analyses
Statistical analyses were completed using RStudio, version 1.0.136 (RStudio). The threshold for statistical significance was set a priori at P less than .001 using a 2-sided test correcting for 35 total comparisons. For the neuropathology analyses, 2 primary models were run. The first was a binary logistic regression with tangle positivity or neuritic plaque positivity set as the outcome. The second model was a proportional odds ordinal logistic regression, setting either Braak stage or CERAD neuritic plaque score as the ordinal outcome. Predictors in the model included age at death, sex, APOE,andasexbyAPOE interaction. APOE-ε2 and APOE-ε4 were evaluated in separate models, and the main effect models were assessed excluding the sex by APOE interaction term. We used a dominant model for ε2 and an additive model for ε4. Follow-up analyses were run stratified by sex. All models were run within each data set individually. For the biomarker analyses, the same prediction models and covariates were assessed using linear regression with baseline CSF β-amyloid 42, CSF total tau (t-tau), or CSF phosphorylated tau set as the continuous outcome. Age at CSF acquisition was used as the age covariate term. Follow-up models were run stratified by sex. All models were run within each data set individually.
Analyses within the CSF and autopsy cohorts were completed separately using the metafor package in R (R Programming), including estimation of fixed effects and heterogeneity across data sets. Correction for multiple comparisons was performed using the Bonferroni procedure accounting for main effects and interactions on 3 biomarker outcomes (CSF β-amyloid 42, t-tau, and phosphorylated tau) and 4 autopsy outcomes (ordinal and binary outcomes of CERAD and Braak staging), resulting in 35 independent tests (corrected α = .0014).
Post hoc analyses evaluated sex by APOE-ε4 interactions on CSF t-tau and phosphorylated tau among amyloid-positive and amyloid-negative individuals. Additional post hoc analyses restricted the sample to cognitively normal individuals, stratified by age group, covaried for education level, restricted autopsy results to longitudinal cohort studies, removed ADNI from the CSF analyses, and restricted to APOE-ε4 homozygotes.
Results
Participant characteristics are presented in Tables 1 and 2 . The biomarker data set included individuals who were, on average, younger, with a higher percentage of men than the autopsy data sets.
Sex Differences and Main Effects of APOE
Main effect results are presented in Table 3 . Women showed higher levels of CSF t-tau, CERAD neuritic plaque score, and Braak tau tangle stage. Similarly, APOE-ε4 was associated with higher levels of biomarker levels and pathology and ε2 was associated with lower biomarker levels and pathology for all metrics.
Sex by APOE Interactions: CSF Biomarker Results
Interaction results are presented in Table 3 . A sex by APOE-ε4 interaction was observed on both t-tau ( Figure 1 ) and phosphorylated tau wherein the association between APOE-ε4 and tau levels was stronger in women than in men ( Figure 2 ).
Sex by APOE Interactions: Autopsy Results
Autopsy interaction results are also presented in Table 3 . There were no significant interactions between sex and APOE on neuropathology. 
Post Hoc Analyses
In post hoc analyses stratified by amyloid status, the sex by APOE-ε4 interaction was present among amyloid-positive individuals (β = 0.41; 95% CI, 0.20 to 0.62; P < .001; eTable 1 in the Supplement) but not amyloid-negative individuals (β = 0.06; 95% CI, −0.18 to 0.31; P = .62; eTable 2 in the Supplement). Additional post hoc analyses stratified by age, restricting the sample to cognitively normal individuals, adjusting for education, restricted to longitudinal cohort studies, removing the ADNI data set, and restricted to APOE-ε4 homozygotes are presented in eTables 3-9 in the Supplement.
Discussion
These findings provide, to our knowledge, the most robust evidence to date of sex differences in the association between APOE-ε4 and CSF tau levels, whereby the effect of APOE is stronger among women compared with men. The observed sex difference was driven by amyloid-positive individuals, suggesting APOE may confer sex-specific risk for downstream neurodegeneration in the presence of enhanced amyloidosis. In contrast to CSF tau levels, we did not observe sex differences in the association between APOE and any biomarkers of amyloidosis or autopsy measures of neurofibrillary tangles. These analyses provide strong evidence of an enhanced association between APOE-ε4 and CSF tau levels among women compared with men, particularly among amyloid positive women. Previous work in ADNI has reported similar sex differences in CSF tau, 14,20 although results have been somewhat mixed depending on the sample included 21 and had never been replicated in an independent cohort. We were able to replicate the sex difference of APOE effects on CSF tau in 3 additional data sets that differ substantially in baseline age and diagnostic status. We also provide evidence of a comparable sex difference in the association between APOE-ε4 and CSF phosphorylated tau for the first time. Several mechanisms could underlie this sex difference in tau, and the hormonal changes that take place during and following menopause represent 1 strong candidate pathway. For example, there is evidence that changes in estrogen levels among women could drive a more severe downstream response to amyloidosis, 35-37 an effect that could be enhanced among ε4 carriers given evidence that estradiol treatment drives APOE release from microglia. 38 A second possibility is that late-life changes in estrogen levels among women have a direct effect on tau. For example, estradiol appears to protect against tau hyperphosphorylation, particularly among female rats, 39 and estrogen receptor α colocalizes with neurofibrillary tangles at autopsy. 40 Interestingly, the α receptor also appears to be responsible for the estrogen-mediated upregulation of APOE expression, 41 suggesting a third possible mechanism in which estrogen and APOE act synergistically in postmenopausal women. Thoughtful, modern experimental approaches are needed to better understand the potential contribution of gonadal hormone differences between men and women in driving the observed APOE sex differences.
42
In contrast to the CSF biomarker results, we did not observe a sex difference in the association between APOE and neurofibrillary tangle load at autopsy. There are a few potential explanations for this counterintuitive observation. Notably, there is growing evidence that CSF tau is a better marker 
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Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau of the intensity of neurodegeneration than the stage of neurofibrillary tangle deposition, 43 suggesting the autopsy and biomarker metrics may represent 2 distinct processes. Therefore, 1 possibility is that sex-specific effects of APOE contribute to differences in neurodegeneration that are not directly mediated by changes in neurofibrillary tangle burden. Other markers of neurodegeneration, including hippocampal volume 44, 45 and cerebral hypometabolism, 21 show sex-specific effects of APOE-ε4 that may underlie the observed differences in CSF tau levels. A second possibility is that the age difference between the autopsy cohorts and biomarker cohorts in this analysis contribute to the observed discrepancy between CSF and autopsy measures of tau. Evidence indicates that both the detrimental effect of APOE-ε4 and the sex difference in APOE-ε4 effect diminishes among the oldest elderly individuals, 3,4 suggesting that subtle age differences could have a large influence on results. In support of such a possibility, we do observe the strongest effects on CSF tau in the younger individuals when stratifying the CSF sample into younger elderly and older elderly adults (eTables 3 and 4 in the Supplement). However, even among the younger elderly adults, we did not observe a sex-specific effect of APOE on autopsy metrics, suggesting this age difference does not fully account for the discrepancy.
In all analyses, we observed a strong association between APOE and amyloidosis that was consistent across men and women. APOE appears to drive risk for clinical AD through an amyloid clearance pathway, 13 so it is not surprising that both
here and previously 46 APOE shows a stronger association with amyloid deposition than tau. Notably, we did not observe differences in the APOE association when comparing younger elderly with older elderly individuals (eTables 3 and 4 in the Supplement), although age differences have been reported.
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The larger sample (and enhanced power) in this analysis likely explains the discrepant findings because Ghebremedhin et al 47 observed patterns consistent with our findings but failed to observe a statistically significance association in the younger group. Importantly, our primary and post hoc analyses support the notion that APOE shows a consistent association with amyloidosis across sex and age and is unlikely to drive observed sex differences in the association between APOE and clinical AD.
48

Strengths and Limitations
This study has multiple strengths, including the large sample size, the integration of both CSF biomarker data and autopsy data, and the extensive sensitivity analyses including explorations into diagnostic status, age, amyloid status, and educational attainment. However, the study is not without limitations. One important limitation is the potential influence of sex differences in survival to older adulthood, which could contribute to a robust survivor effect amongmen compared with women. As others have previously highlighted, selective survival of men with substantially lower cardiovascular risk profiles may contribute to sex differences in AD risk in older adulthood. 49 It is also notable that the sex-specific effect of APOE-ε4 on microbleeds is actually in the inverse direction, 50 with men showing a stronger association than women, suggesting that sex-specific effects of APOE-ε4 may have differential effects on AD and non-AD pathologies, even in the face of potential survivor bias. Future work is needed to develop and integrate modern statistical approaches to estimate and account for the effect of survival bias, particularly in analyses of sex-specific molecular drivers of AD and non-AD neuropathologies. The cross-sectional nature of the biomarker and autopsy data also limits our ability to make causal inferences, particularly with respect to the sequential ordering of neuropathologies or CSF biomarker deposition. Finally, the cohorts were relatively homogeneous across race and ethnicity, with some cohorts being exclusively white. Thus, findings may not be generalizable to other racial and ethnic groups that may be at greater risk of AD. Results will need to be extended to cohorts with greater diversity.
Conclusions
These results provide strong evidence of sex differences in the association between APOE and CSF tau levels that do not appear to reflect differences in neurofibrillary tangle deposition. Future work should evaluate the genetic drivers of plaques, tangles, neurodegeneration, and cognitive impairment in a sex-specific manner to identify novel pathways of risk. 
